
    
      Based on an overall review of safety and preliminary efficacy data done on 01-Dec-2014
      showing marginal anti-tumor activity and newly emerged treatment options, a decision was
      taken to stop further development of this combination in patients with advanced or metastatic
      squamous NSCLC and Phase II of the study was not conducted.
    
  